Background.: Paclitaxel administered on a weekly basis has been reported to possess both anti-angiogenic and apoptotic-inducing effects. We investigated the activity of a weekly continuous paclitaxel regimen in patients with recurrent platinum-resistant ovarian cancer. Methods.: Patients with recurrent ovarian cancer and documented platinum-resistant disease were treated with weekly intravenous paclitaxel(60-80 mg/m2) continuously for up to 24 weeks over an 18-month period. Prospective data collection included: information on patients’demographics together with disease-and treatment-related toxicities. Response was evaluated using radiographic and CA125 criteria. Chi-squ- are tests were used to test for significant associations between categorical variables. Progression-free survival and overall survival time from commencement of weekly treatment were estimated using the Kaplan-Meier method. All P values less than 0.05 were considered to be statistically significant. Results.: Thirty-four patients were treated on protocol. Five patients(15%) reported grade 3/4 neurotoxicity at the end of 12 weeks. No dose reduction or treatment delay was required. No significant hematologic toxicity was observed. Responses were evaluable in thirty-two patients. Complete response was observed in three patients(9%), and another 14 patients showed a partial response(44%). Seven patients(22%) had disease stabilization. The estimated median progression-free survival and overall survival were 6.10 months(95%CI:3.81-8.39) and 10.43 months(95%CI: 8.49-12.38) respectively from the start of the regimen. Conclusion.: Continuous weekly paclitaxel is a well-tolerated and active regimen in patients with recurrent platinum-resistant ovarian cancer. Background: Paclitaxel administered on a weekly basis has been reported to possess both anti-angiogenic and apoptotic-inducing effects. We investigated the activity of a weekly continuous paclitaxel regimen in patients with recurrent platinum-resistant ovarian cancer. Methods .: Patients with recurrent ovarian cancer and documented platinum-resistant disease were treated with weekly intravenous paclitaxel (60-80 mg / m2) for up to 24 weeks over an 18-month period. Prospective data collection included: information on patients’demographics together with disease-and Treatment-related toxicities. Response was evaluated using radiographic and CA125 criteria. Chi-squ- are tests were used to test for significant associations between categorical variables. Progression-free survival and overall survival time from commencement of weekly treatment were estimated using the Kaplan- Meier method. All P values ​​less than 0.05 were considered to be significant significant. Results. Thirty-f Five patients (15%) reported grade 3/4 neurotoxicity at the end of 12 weeks. No dose reduction or treatment delay was required. No significant hematologic toxicity was observed. Responses were evaluable in thirty-two patients Seven patients (22%) had disease stabilization. The estimated median progression-free survival and overall survival were 6.10 months (9%), and another 14 patients showed a partial response 95% CI: 3.81-8.39) and 10.43 months (95% CI: 8.49-12.38) respectively from the start of the regimen. Conclusion .: Continuous weekly paclitaxel is a well-tolerated and active regimen in patients with recurrent platinum-resistant ovarian cancer.